In triple-negative breast cancer (TNBC), cells with high SLC7A11 expression consume more Gln and are more sensitive to Gln starvation compared to other breast cancer cells.134 SLC7A11 is also highly expressed in lung, PDAC, renal, and liver cancers.135–137 Moreover, Badgley et al. found that deletion of SLC7A11 has no effect on normal pancreatic tissue development in mice but severely impairs KRAS-driven PDAC growth.137 The non-necessity of SLC7A11 under physiological conditions and the high expression of SLC7A11 in tumors make SLC7A11 a promising target for cancer therapy (Table 1). This evidence concerns the gene KRAS and breast cancer.